R&D News | pharmaphorum

News

Teva settles Oklahoma opioid lawsuit ahead of trial

Teva has opted to settle the first trial among hundreds of cases that accuse it and other drugmakers of helping to fuel the opioid addiction epidemic in the US.

News

Pfizer’s Lyrica fails phase 3 trial in epilepsy

Pfizer’s Lyrica has failed to meet its primary endpoint in a phase 3 trial in primary generalised tonic-clonic (PGTC) seizures.

Views & Analysis

R&D Roundup: Novartis pipeline, CRISPR funding and Opdivo di...

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.

News

EU regulators accept Novartis' triple asthma combo

European regulators have accepted Novartis’ filing for a triple combination therapy for asthma known as QVM149, triggering payments to development partners Vectura and Sosei.

News

Novartis shows off pipeline - including 25 potential blockbu...

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

UK's LifeArc charity nets $1.3 billion Keytruda windfall

The UK’s medical research charity LifeArc has received a windfall of nearly $1.3 billion after selling a portion of its royalty interest in Merck & Co’s blockbuster cancer drug Keytruda

Teva settles Oklahoma opioid lawsuit ahead of trial

Pfizer’s Lyrica fails phase 3 trial in epilepsy

R&D Roundup: Novartis pipeline, CRISPR funding and Opdivo di...

EU regulators accept Novartis' triple asthma combo

Novartis shows off pipeline - including 25 potential blockbu...

UK's LifeArc charity nets $1.3 billion Keytruda windfall

Antiviral development in the age of AI: From pre-IND to earl...

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks